The launch of 750mcg teriparatide solution in Australia has involved significant sales . Currently, it’s primarily offered for patients with severe osteoporosis where other therapies have failed . Obtaining this higher-dose formulation is challenging due to physician approval requirements and limited clinic stock . Despite some pharmacies may off